NASDAQ : TECX
Tectonic Therapeutic, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 19.56 USD (Oct 30, 2026, 1:42 PM EDT) · Market cap 382.39M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 386.69M |
| Enterprise Value | 164.02M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 19.55M |
| Shares Outstanding | 19.55M |
| Shares Change (YoY) | +14.76% |
| Shares Change (QoQ) | +1.04% |
| Owned by Insiders (%) | 33.02% |
| Owned by Institutions (%) | 65.65% |
| Float | 11.89M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.70 |
| P/TBV Ratio | 1.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 22.29 |
| Quick Ratio | 21.90 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,373.13 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -33.80% |
| Return on Assets (ROA) | -22.29% |
| Return on Invested Capital (ROIC) | -23.09% |
| Return on Capital Employed (ROCE) | -41.88% |
| Weighted Average Cost of Capital (WACC) | 6.95% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.43M |
| Employee Count | 60 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 331,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.50 |
| 52-Week Price Change | +6.23% |
| 50-Day Moving Average | 26.01 |
| 200-Day Moving Average | 28.09 |
| Relative Strength Index (RSI) | 30.77 |
| Average Volume (20 Days) | 184,546 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.22M |
| Short Previous Month | 2.22M |
| Short % of Shares Out | 11.38% |
| Short % of Float | 18.71% |
| Short Ratio (days to cover) | 9.07 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -94.93M |
| Pretax Income | -85.46M |
| Net Income | -85.79M |
| EBITDA | -93.66M |
| EBIT | -94.93M |
| Earnings Per Share (EPS) | -$4.56 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 227.07M |
| Total Debt | 4.40M |
| Net Cash | 222.67M |
| Net Cash Per Share | $11.39 |
| Equity (Book Value) | 223.85M |
| Book Value Per Share | 11.64 |
| Working Capital | 220.73M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -72.14M |
| Capital Expenditures | -279,000 |
| Depreciation & Amortization | 1.26M |
| Net Borrowing | -451,000 |
| Free Cash Flow | -72.42M |
| FCF Per Share | -$3.70 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -14.76% |
| Shareholder Yield | n/a |
| Earnings Yield | -23.08% |
| FCF Yield | -18.73% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $71.00 |
| Price Target Difference | 258.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |